Eckert & Ziegler Gains European Approval for Theralugand®

Berlin-based Eckert & Ziegler Radiopharma GmbH announced that it has received approval from the European Commission for its radiopharmaceutical product, Theralugand® - Lutetium-177 chloride (n.c.a). This approval marks a significant step forward for the company, enabling the use of Theralugand® in routine clinical applications throughout the European Economic Area (EEA).

Theralugand® is a high-purity radioisotope compliant with GMP standards, designed for labeling therapeutic radiopharmaceuticals. The approval expands its potential use in innovative cancer therapies, such as treatments targeting neuroendocrine tumors and metastatic prostate cancer, previously limited to investigational use.

Eckert & Ziegler collaborates with global pharmaceutical companies to develop Lutetium-177-based therapies, furthering the scope of targeted radiotherapies. The approval is a pivotal achievement in making advanced treatments widely accessible across Europe.